]>
IRCT20200921048794N1 IRCT 2020-11-19 Hamedan University of Medical Sciences Evaluation of the Effects of L-carnitine Supplementation on Patients with COVID-19 Evaluation of the Effects of L-carnitine Supplementation on Clinical Outcomes in Hospitalized Patients with COVID-19 2021-02-19 anticipated 64 Complete https://irct.ir/trial/51120 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: We put 2 sheets A and two sheets B in an envelope and each time we remove one of the sheets, we place the patient in the control or intervention group. The removed sheet will not be returned to the envelope until the all of sheets in the envelope be finished. After randomly pulling out all four sheets, all sheets are returned to the envelope and the above procedure will be continued for the next four patients until the desired sample size is reached. 3 COVID-19. Intervention 1: Control group: This hospitalized group receives only their routine medication regimen which includes Dexamethasone, Interferon beta and Favipiravir. Intervention 2: Intervention group: The intervention group in addition to their usual treatment regimen received 1000 mg L-carnitine tablets of Karen Company for 5 days and 3 g daily, three oral tablets daily. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information
public Mehran Ghasemi
Faculty of Pharmacy, Hamadan University of Medical Sciences
Hamedan Iran (Islamic Republic of) 6517838678 +98 81 3838 1593 mehranghasemy76@gmail.com Hamedan University of Medical Sciences scientific Rasool Haddadi
Faculty of Pharmacy, Hamadan University of Medical Sciences
Hamedan Iran (Islamic Republic of) 6517838678 +98 81 3838 1593 haddadi.rasool@gmail.com Hamedan University of Medical Sciences Iran (Islamic Republic of) Age 18 to 60 years Positive PCR Test Hospitalization Existence of Corona Virus Symptoms According to the Instructions of the Ministry of Health Mild to Moderate Disease Severity 18 years 60 years Both Pregnancy Breastfeeding Severe Cardiovascular Disease HIV Infection History of Taking L-carnitine Supplementation in the Past Month Requires Care in the ICU Taking Anti-Inflammatory Drugs out of the Medication Regimen Patients with High and Critical Disease Severity Patient Dissatisfaction to Enter the Plan U07.1 COVID-19, Virus identified Treatment - Drugs Treatment - Drugs Control group: This hospitalized group receives only their routine medication regimen which includes Dexamethasone, Interferon beta and Favipiravir. Intervention group: The intervention group in addition to their usual treatment regimen received 1000 mg L-carnitine tablets of Karen Company for 5 days and 3 g daily, three oral tablets daily. C-Reactive Protein (CRP). Timepoint: At the Beginning of Intervention (the Zero day) and the End of Intervention (Fifth day ). Method of measurement: Blood test. Erythrocyte Sedimentation Rate (ESR). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test. O2 Saturation. Timepoint: Beginning and End of the Intervention. Method of measurement: Pulse Oximeter. Complete Blood Count (CBC). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test. White Blood Cell (WBC). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test. Alanine Aminotransferase (ALT). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test. Lactate Dehydrogenase (LDH). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test. Creatine Phosphokinase (CPK). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test. Creatinine. Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test. Urea. Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test. Prothrombin Time (PT). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test. Red Cell Distribution Width (RDW). Timepoint: Beginning and End of the Intervention. Method of measurement: Blood test. Fever. Timepoint: Beginning and End of the Intervention. Method of measurement: Patient File. Cough. Timepoint: Beginning and End of the Intervention. Method of measurement: Questionnaire. Mortality Rate. Timepoint: During the intervention. Method of measurement: Death of the Patient. Duration of Hospitalization. Timepoint: Beginning and End of the Intervention. Method of measurement: Days. ICU Referral. Timepoint: During the Intervention. Method of measurement: Observational. Requires Ventilation. Timepoint: During the Intervention. Method of measurement: Observational. Hamedan University of Medical Sciences Approved 2020-10-24 Ethics Committee of Hamadan University of Medical Sciences Hamadan University of Medical Sciences, Mahdieh Street, in front of People's Park Hamedan Hamadan Iran (Islamic Republic of)